AV-412

CAT: 0804-HY-10346-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-10346-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
AV-412 (MP412) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively.
CAS Number
[451493-31-5]
Product Name Alternative
MP412
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/AV-412.html
Concentration
10mM
Purity
99.17
Solubility
DMSO : ≥ 28 mg/mL
Smiles
O=S(C1=CC=C(C)C=C1)(O)=O.C=CC(NC2=CC3=C(NC4=CC=C(F)C(Cl)=C4)N=CN=C3C=C2C#CC(N5CCN(C)CC5)(C)C)=O.O=S(C6=CC=C(C)C=C6)(O)=O
Molecular Formula
C41H44ClFN6O7S2
Molecular Weight
851.41
Precautions
H302, H315, H319, H335
References & Citations
[1]Suzuki T, et al. Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptorand ErbB2 tyrosine kinase inhibitor. Cancer Sci. 2007 Dec;98 (12) :1977-84.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
EGFR/ErbB1/HER1; ErbB2/HER2
Citation 01
Cancer Med. 2024 May;13 (10) :e7083.|Nature. 2025 Nov 26.|Proc Natl Acad Sci U S A. 2019 Feb 19;116 (8) :2996-3005. |Sci Data. 2024 Sep 19;11 (1) :1024.|Science. 2017 Dec 1;358 (6367) :eaan4368.

Popular Products